{"classes":[{"categories":[{"measurements":[{"comment":"NA: Not estimable due to insufficient events observed","groupId":"OG000","lowerLimit":"1.0","upperLimit":"NA","value":"2.4"},{"groupId":"OG001","lowerLimit":"0.5","upperLimit":"0.6","value":"0.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"157"},{"groupId":"OG001","value":"76"}],"units":"Participants"}],"description":"TTF was defined as the time from date of randomization to an event of treatment failure. Treatment failure was defined as meeting a lack of efficacy criterion or discontinuing treatment due to any reason.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants randomized to asciminib 40mg BID","id":"OG000","title":"Asciminib"},{"description":"Participants randomized to bosutinib 500mg QD","id":"OG001","title":"Bosutinib"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): The FAS comprised of all randomized participants.","reportingStatus":"POSTED","timeFrame":"From the first dose of treatment up to 5 years, through treatment completion, an average of 2.3 years, approximately","title":"Time to Treatment Failure (TTF)","type":"SECONDARY","unitOfMeasure":"Year"}